Michael Jain, MD, PhD
Michael Jain, MD, PhD, Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, Tampa, Florida, commented on Dr. Kilgore’s findings. Dr. Jain was coauthor of a study by the U.S. Lymphoma CAR T Consortium that presented real-world data on 298 patients with lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy (ie, axicabtagene ciloleucel) with 13.8 months of follow-up.1
“In our previous analysis, patients who were ineligible for clinical trials for various reasons had reasonably good outcomes after [CAR T-cell therapy], but not quite as good as those who met eligibility criteria. When we looked at individual factors related to outcomes, poor [Eastern Cooperative Oncology Group] performance status stood out,” Dr. Jain said.
“In my experience, patients in remission have few health-care needs 3 months out from [CAR T-cell therapy]. Our patient-reported outcomes at Moffitt showed that patients who are in remission have similar or improved outcomes,” Dr. Jain commented.
DISCLOSURE: Dr. Jain has served in a consulting or advisory role for Kite/Gilead and has been reimbursed for travel, accommodations, or other expenses by Kite/Gilead.
1. Nastoupil LJ, Jain MD, Spiegel JY, et al: Axicabtagene ciloleucel CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma: Real world experience. Blood 132(suppl 1):91, 2018.
Once considered highly experimental, chimeric antigen receptor (CAR) T-cell therapy is now an established third-line treatment option for B-cell lymphomas and leukemias. CAR T-cell therapy has saved the lives of people who would otherwise have run out of treatment options. But the question is...